Skip to content

This round closed on 22 September 2026. The details below are from that round.

Browse open KWF calls.

KWF

Lead4Life PPP Call 2026

€0.5M–€2M per project (total programme: €5M)||Up to 4 years

12:00 noon; full proposals only — matchmaking phase precedes

Last seen in a scan/import: .

Catalog updated: .

These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.

Closed for now. See which open grants match your research. 30s, no email. See my matches →

The KWF Lead4Life PPP Call 2026 funds public-private partnership consortia to develop lead-212 radiopharmaceutical therapies and enabling production technologies, with grants of €0.5M-€2M per project over up to four years. This Health~Holland programme is open to Dutch research institutions partnered with industry, and requires a mandatory Consortium Agreement among all participants. The call runs in two stages: a matchmaking phase followed by full proposal submission, closing 22 September 2026.

Details

Funder KWF
Budget €0.5M–€2M per project (total programme: €5M)
Duration Up to 4 years
Consortium Required — public-private partnership consortium; Consortium Agreement between all participants is mandatory
Application 2-stage: matchmaking phase → full proposal (opened 5 May 2026, closes 22 September 2026)
Frequency One-off
Eligible countries NL

Recently updated

catalog cleanup 2026-07-04: duplicate row (canonical sibling kept)

Eligibility & scope

Health~Holland PPP programme focused on lead-212 (Pb-212) radiopharmaceuticals for cancer treatment. Projects must address either (1) Pb-212 production & supply chain or (2) enabling technologies for clinical introduction. Requires active private-party participation, a Consortium Agreement, and compliance with Health~Holland PPP and TKI-LSH requirements. Private party must not be an undertaking in difficulty (RVO declaration required). Proposals submitted via KWF GMS; Dutch Summary reviewed by Patient Advisory Committee.

Who Should Apply

  • •Dutch academic or hospital research institutions with lead-212 or radiopharmaceutical expertise
  • •Consortia including at least one private-sector partner (industry, biotech, or pharmaceutical company)
  • •Projects focused on lead-212 medical isotope production, radiochemistry, or therapeutic application in cancer
  • •Teams prepared to establish a formal Consortium Agreement before submission

Key Dates

  • •Matchmaking phase followed by full proposal window: 5 May, 22 September 2026 (full proposals at 12:00 noon GMT)
  • •Participating institutes not yet registered in GMS must request access at least 6 weeks before the deadline
  • •Projects run for up to four years

Tips for Applicants

  • ✓Industry partner commitment is non-negotiable; early engagement with a named company strengthens matchmaking outcomes and consortium credibility.
  • ✓The Dutch Summary is reviewed by the Patient Advisory Committee, pitch the clinical benefit and real-world relevance of your lead-212 approach in plain language.
  • ✓Secure GMS system access early if your institute is new to Health~Holland PPPs; registration delays can jeopardise submission.

Frequently Asked Questions

What is the budget range for the KWF Lead4Life PPP Call 2026?

Grants range from €0.5M to €2M per project over up to four years, with a total programme budget of €5M.

Can I apply to the Lead4Life PPP Call without an industry partner?

No, a private-sector partner is mandatory for all proposals; projects must be structured as public-private partnerships with a formal Consortium Agreement.

What is the deadline for the KWF Lead4Life PPP Call 2026?

Full proposals close at 12:00 noon GMT on 22 September 2026; the matchmaking phase opens 5 May 2026.

Who is eligible to apply to the Lead4Life PPP Call?

Dutch research institutions (academic or hospital) partnered with industry, focusing on lead-212 radiopharmaceutical production or cancer therapies.

Is the Consortium Agreement required before submission?

Yes, all participants must establish and sign a Consortium Agreement before submitting the full proposal.

kwflead-212radiopharmaceuticalcancer-therapypublic-private-partnershipnetherlandsconsortium-requiredtranslational

Related on Grantsby

Summary generated by AI based on published grant information. Always verify details on the funder's website.

Similar grants

Browse all open grants →

Browse Related

This call has closed. See what's open now.

Get matched against every open call from KWF and the rest of the 65 funders we track, rechecked every week. 30 seconds, no signup needed to preview.

See my matches free →